ReviewFrontiers in nutrition2026
Urolithins in clinical translation: from gut microbial metabolites to precision interventions.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urolithins are gut microbiota-derived metabolites generated from ellagitannins and ellagic acid, and have emerged as promising mediators at the diet-microbiota-host interface. Interest in this metabolite family has increased substantially owing to growing evidence that urolithins, particularly urolithin A, influence mitochondrial quality control, autophagy, inflammatory signaling, and metabolic homeostasis across multiple tissues. These mechanistic properties have positioned urolithins as candidate interventions for aging-related functional decline, cardiometabolic disorders, neuroinflammatory conditions, and other chronic diseases characterized by impaired cellular resilience. However, their path to clinical application remains incompletely defined. In this Review, we synthesize current knowledge on the origin, microbial biotransformation, metabotypes, pharmacokinetics, and exposure biology of urolithins, with particular attention to the determinants of interindividual variability and the unresolved question of which molecular species are truly active
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.